公开(公告)号：US20240100003A1

公开(公告)日：2024-03-28

申请号：US18535865

申请日：2023-12-11

申请人： United Therapeutics Corporation

发明人： Roger Jeffs ,  Thomas Petersen ,  Roger M. Ilagan ,  Michael Wade

IPC分类号： A61K31/192 ,  A61K31/557 ,  A61K35/28 ,  C12N5/0775

CPC分类号： A61K31/192 ,  A61K31/557 ,  A61K35/28 ,  C12N5/0663 ,  C12N2501/00 ,  C12N2501/02

摘要： Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

公开(公告)号：US20230255892A1

公开(公告)日：2023-08-17

申请号：US17991697

申请日：2022-11-21

申请人： Supernus Pharmaceuticals, Inc.

发明人： Argaw Kidane ,  Padmanabh P Bhatt

IPC分类号： A61K9/28 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585 ,  A61K31/192

CPC分类号： A61K9/282 ,  A61K9/0004 ,  A61K9/28 ,  A61K9/286 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2013 ,  A61K9/2077 ,  A61K9/2826 ,  A61K31/192 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585

摘要： An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.

公开(公告)号：US20230218560A1

公开(公告)日：2023-07-13

申请号：US18110954

申请日：2023-02-17

申请人： Pronova Biopharma Norge As

发明人： Svein Olaf HUSTVEDT ,  Preben Houlberg Olesen ,  Gunnar Berge ,  Jo Erik Johnsrud Klaveness

IPC分类号： A61K31/232 ,  A61K9/48 ,  A61K31/202 ,  A61K9/08 ,  A61K9/20 ,  A23L33/115 ,  A23L33/10 ,  A61K31/557 ,  A61K31/201 ,  A61K9/107

CPC分类号： A61K31/232 ,  A61K9/4858 ,  A61K31/202 ,  A61K9/08 ,  A61K9/4866 ,  A61K9/20 ,  A23L33/115 ,  A23L33/10 ,  A61K9/4825 ,  A61K31/557 ,  A61K31/201 ,  A61K9/1075

摘要： A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

公开(公告)号：US11491143B2

公开(公告)日：2022-11-08

申请号：US16728615

申请日：2019-12-27

申请人： AI Therapeutics, Inc.

发明人： Thomas Armer ,  Lawrence S. Melvin, Jr. ,  Jonathan M. Rothberg ,  Henri Lichenstein

IPC分类号： A61K31/436 ,  A61K45/06 ,  A61K9/00 ,  A61K9/12 ,  A61K31/557 ,  A61K9/16

摘要： The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.

公开(公告)号：US20220339237A1

公开(公告)日：2022-10-27

申请号：US17472128

申请日：2021-09-10

申请人： Cella Therapeutics, LLC

发明人： Rhett M. Schiffman ,  Lukas Scheibler

IPC分类号： A61K38/08 ,  A61P27/06 ,  A61K31/192 ,  A61K38/07 ,  A61K47/64 ,  A61K47/55 ,  A61K31/165 ,  A61K38/17 ,  A61K38/22 ,  A61K45/06 ,  A61K31/557

摘要： This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

公开(公告)号：US11433082B2

公开(公告)日：2022-09-06

申请号：US16672170

申请日：2019-11-01

申请人： CyDex Pharmaceuticals, Inc.

发明人： Naomi Esaki ,  James D. Pipkin

IPC分类号： A61K31/557 ,  A61K31/74 ,  A61K9/00 ,  A61K47/40

摘要： An aqueous composition of latanoprost and SAE-CD is provided. The composition possesses improved stability over otherwise similar compositions excluding SAE-CD. Methods of and systems for treating disease, disorders, conditions or symptoms of the eye that are therapeutically responsive to latanoprost are also provided.

公开(公告)号：US20220062210A1

公开(公告)日：2022-03-03

申请号：US17469745

申请日：2021-09-08

申请人： United Therapeutics Corporation

发明人： Roger Jeffs ,  Thomas Petersen ,  Roger M. Ilagan ,  Michael Wade

IPC分类号： A61K31/192 ,  C12N5/0775 ,  A61K35/28 ,  A61K31/557

摘要： Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

公开(公告)号：US11185538B2

公开(公告)日：2021-11-30

申请号：US17238550

申请日：2021-04-23

申请人： Aerie Pharmaceuticals, Inc.

发明人： Casey Kopczynski ,  Cheng-Wen Lin ,  Jill Marie Sturdivant ,  Mitchell A. deLong

IPC分类号： A61K31/472 ,  A61K31/4725 ,  A61K9/00 ,  A61K9/08 ,  A61K47/55 ,  A61K47/54 ,  C07D409/12 ,  C07D217/22 ,  A61K31/5575 ,  A61K31/559 ,  A61K31/557

摘要： Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

公开(公告)号：US11166930B2

公开(公告)日：2021-11-09

申请号：US16348087

申请日：2017-11-16

申请人： RETROTOPE, INC.

发明人： Mikhail Sergeevich Shchepinov

IPC分类号： A61K31/22 ,  A61K31/215 ,  A61K31/20 ,  A61K31/202 ,  A61P25/28 ,  A61B5/055 ,  A61B5/00 ,  G01N33/573 ,  G01N33/68 ,  C12Q1/32 ,  A61P25/00 ,  A61K31/375 ,  A61K31/557 ,  A61K31/66 ,  A61K31/122 ,  A61K31/355

摘要： Methods are provided of identifying a subject having impaired aldehyde dehydrogenase activity; and administering to the subject a compound comprising an isotopically-modified polyunsaturated fatty acid, an isotopically-modified polyunsaturated fatty acid ester, an isotopically-modified polyunsaturated fatty acid thioester, an isotopically-modified polyunsaturated fatty acid amide, a polyunsaturated fatty acid mimetic, or an isotopically-modified polyunsaturated fatty acid pro-drug, the compound having an isotopic modification that reduces oxidation of the compound, thereby reducing production in the subject of substrate for aldehyde dehydrogenase. Some aspects provide coadministering an isotopically-modified polyunsaturated fatty acid and an oxylipin.

公开(公告)号：US11141399B2

公开(公告)日：2021-10-12

申请号：US17106741

申请日：2020-11-30

申请人： Amarin Pharmaceuticals Ireland Limited

发明人： Mehar Manku ,  Pierre Wicker ,  Rene Braeckman ,  Paresh Soni ,  Joseph S. Zakrzewski

IPC分类号： A61K31/232 ,  A61K33/04 ,  A61K31/198 ,  A61K31/575 ,  A61K45/06 ,  A61K31/07 ,  A61K31/202 ,  A61K31/05 ,  A61K9/48 ,  A61K31/557

摘要： In various embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.